Products
Ceftarolinefosamil is commercially available as a powder for the preparation of a concentrate for an infusion solution (Zinforo). It has been approved in many countries since 2013.
Structure and properties
Ceftarolinefosamil (C22H21N8O8PS4, Mr = 684.7 g/mol) is present in drugs as ceftarolinefosamil monoacetate monohydrate, a yellowish-white powder. Ceftarolinefosamil is a prodrug that is enzymatically converted to the active ceftaroline in plasma by a phosphatase.
Effects
Ceftaroline (ATC J01DI02) has bactericidal properties against Gram-positive and Gram-negative bacteria and is also effective against MRSA and PNSP. The effects are based on inhibition of bacterial cell wall synthesis. Ceftaroline has a short half-life of 2.5 hours.
Indications
For the treatment of bacterial infectious diseases:
- Complicated skin and soft tissue infections.
- Ambulatory-acquired pneumonia
Dosage
According to the professional information. The drug is administered as an intravenous infusion.
Contraindications
- Hypersensitivity to beta-lactam antibiotics or excipients.
For complete precautions, see the drug label.
Interactions
Complete information on drug-drug interactions is not available.
Adverse effects
The most common possible adverse effects include diarrhea, headache, nausea, and pruritus. As with other cephalosporins, hypersensitivity reactions may occur.
